



Attorney Docket No. Le A 33 878

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor application of: Alonso-Alija, et al.

Group No.:

Serial No.: 10/088,060

Examiner:

Filed: 03/13/2002

For: "Novel Derivatives of Dicarboxylic Acid Having Pharmaceutical Properties"

1626
PATENT
AUG 2 3 2002
TECH CENTER 1600-2900

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: AUG 1 3 2002

Ms. Mariellen Chapdelaine
Signature of Person Certifying

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed *before* the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.


Respectfully submitted,

Reg. No. 31,018

Telephone: (203) 812-2712

Date: 12 Aug '02

William F. Gray
William F. Gray
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516



U.S. Department of Commerce
Patent and Trademark Office

Serial No.
10/088,060

Group Art Unit

Filing Date
03/13/2002

Atty. Docket No.
Le 423 878

**SUPPLEMENTAL
INFORMATION DISCLOSURE CITATION**

Applicant(s) Alonso-Alija, et al.

RECEIVED
AUG 23 2002
TECH CENTER 16002900

U.S. PATENT DOCUMENTS

*	DOCUMENT NO.	DATE MM/DD/YY	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
---	--------------	------------------	------	-------	-----------	----------------------------------

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.								DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB-CLASS	TRANSLATION	
													YES	NO
	F3	0	3	4	5	0	6	8	06/12/89	EP				
	F4	9	3	0	0	3	5	9	07/01/93	WO				
	F5	9	8	1	6	2	2	3	23/04/98	WO				
	F6	9	8	1	6	5	0	7	23/04/98	WO				
	F7	9	8	2	3	6	1	9	04/06/98	WO				
	F8	0	3	4	1	5	5	1	15/11/89	EP				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

R1	Ko, F., Wu, C., Kuo, S., Lee, F., Teng, C., "YC-1, A Novel Activator of Platelet Guanylate Cyclase", Blood, 84: 4226-4233 (1994)
R2	Mulsch, A., Bauersachs, J., Schafer, A., Stasch, J., Kast, R., Busse, R., "Effect of YC-1, An NO-Independent, Superoxide-Sensitive Stimulator of Soluble Guanylyl Cyclase, On Smooth Muscle Responsiveness to Nitrovasodilators", Br. J. Pharmacol., 120: 681-689 (1997)
R3	Glass, D., Frey, W., Carr, D., Goldberg, N., "Stimulation of Human Platelet Guanylate Cyclase by Fatty Acids", J. Biol. Chem., 252: 1279-1285 (1977)
R4	Petibone, D., Sweet, C., Risley, E., Kennedy, T., "A Structurally Novel Stimulator of Guanylate Cyclase With Long-Lasting Hypotensive Activity in the Dog", Eur. J. Pharmacol., 116: 307-312 (1985)
R5	Yu, S., Kuo, S., "Vasorelaxant Effect of Isoliquiritigenin, A Novel Soluble Guanylate Cyclase Activator, In Rat Aorta", Br. J. Pharmacol., 114: 1587-1594 (1995)
R6	Gerzer, R., Bohme, E., Hofmann, F., Schultz, G., "Soluble Guanylate Cyclase Purified From Bovine Lung Contains Heme and Copper", FEBS Lett., 132: 71-74 (1981)
R7	Hoenicka, M., Becker, E., Apeler, H., Sirichoke, T., Schroder, H., Gerzer, R., Stasch, J., "Purified Soluble Guanylyl Cyclase Expressed in a Baculovirus/Sf9 System: Stimulation by YC-1, Nitric Oxide, and Carbon

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Monoxide", J. Mol. Med., 77; 14-23 (1999)

Ignarro, L., "Regulation of Cytosolic Guanylyl Cyclase By Porphyrins and Metalloporphyrins", Adv. Pharmacol., 26; 35-65 (1994)

R9

Mulsch, A., Bauersachs, J., Stasch, J., Busse, R., "Potentiation of Vascular Responses To No-Donors By a No-Independent Activator of Soluble Guanylyl Cyclase", Naunyn Schmiedebergs Arch. Pharmacol. 355; R47

RECEIVED
AUG 23 2002
INTELLIGENCE CENTER 1800/2900

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.